These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 8468121)

  • 1. Enhancement of various non-specific immune effector functions in mice by local injection of aclacinomycin A adsorbed onto activated carbon particles (ACR-CH).
    Sakakura C; Takahashi T; Hagiwara A; Yamane T; Itoh M; Shobayashi S; Sasaki S; Ozaki K; Tsujimoto H
    Int J Immunopharmacol; 1993 Feb; 15(2):245-54. PubMed ID: 8468121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of cytotoxicity in mouse regional lymph nodes by local tissue injection of aclacinomycin A.
    Sakakura C; Takahashi T; Sawai K; Hagiwara A; Yamane T; Itoh M; Sasabe T; Lee M; Shobayashi S
    Lymphology; 1992 Sep; 25(3):114-9. PubMed ID: 1434786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Enhancement of cytotoxicity in the regional lymph node cells by local injection of carbon particles adsorbing aclacinomycin a: preliminary report].
    Sakakura C; Takahashi T; Sawai K; Hagiwara A; Yamane T; Ito M; Shobayashi S
    Nihon Geka Gakkai Zasshi; 1992 Jun; 93(6):667. PubMed ID: 1630446
    [No Abstract]   [Full Text] [Related]  

  • 4. [Trial of a treatment for lymph node metastases in patients with breast cancer using aclarubicin bound to activated carbon particles].
    Imanishi T; Sakakibara T; Yamazaki J; Ohyama T; Shirasu M; Tsujimoto H; Ohgaki M; Shimotsuma M; Hagiwara A; Sawai K
    Gan To Kagaku Ryoho; 1995 Sep; 22(11):1635-7. PubMed ID: 7574780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Visualising lymph nodes by aclarubicin bound to activated carbon particles in breast cancer surgery].
    Imanishi T; Hagiwara A; Sawai K; Yamaguchi T; Sakakura C; Shirasu M; Ohgaki M; Yamasaki J; Togawa T; Takahashi T
    Gan To Kagaku Ryoho; 1997 Sep; 24(12):1796-8. PubMed ID: 9382535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Enhancement of therapeutic efficacy of aclarubicin against lymph node metastases using a new dosage form: aclarubicin adsorbed on activated carbon particles].
    Sakakura C; Takahashi T; Sawai K; Hagiwara A; Shimotsuma M; Shobayashi S; Ozaki K; Sasaki S; Tsujimoto H; Shirasu M
    Gan To Kagaku Ryoho; 1992 Aug; 19(10 Suppl):1560-3. PubMed ID: 1530308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective distribution of aclarubicin to regional lymph nodes with a new dosage form: aclarubicin adsorbed on activated carbon particles.
    Hagiwara A; Takahashi T; Iwamoto A; Yoneyama C; Matsumoto S; Muranishi S
    Anticancer Drugs; 1991 Jun; 2(3):261-6. PubMed ID: 1802020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective drug delivery to peri-tumoral region and regional lymphatics by local injection of aclarubicin adsorbed on activated carbon particles in patients with breast cancer--a pilot study.
    Hagiwara A; Takahashi T; Sawai K; Sakakura C; Shirasu M; Ohgaki M; Imanishi T; Yamasaki J; Takemoto Y; Kageyama N
    Anticancer Drugs; 1997 Aug; 8(7):666-70. PubMed ID: 9311442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of therapeutic efficacy of aclarubicin against lymph node metastases using a new dosage form: aclarubicin adsorbed on activated carbon particles.
    Sakakura C; Takahashi T; Sawai K; Hagiwara A; Ito M; Shobayashi S; Sasaki S; Ozaki K; Shirasu M
    Anticancer Drugs; 1992 Jun; 3(3):233-6. PubMed ID: 1525403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adsorption and desorption of aclarubicin into and from activated carbon particles as drug carrier--an in vitro study].
    Matsumoto S; Iwamoto A; Yoneyama C; Hagiwara A; Takahashi T; Yoshikawa H; Muranishi S
    Gan To Kagaku Ryoho; 1991 Feb; 18(2):227-31. PubMed ID: 1992916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new dosage form comprising a suspension of activated carbon particles adsorbing aclarubicin: toxicity in mice.
    Hagiwara A; Takahashi T; Iwamoto A; Yoneyama C; Ito M; Sasabe T; Muranishi S; Matsumoto S
    Anticancer Drugs; 1991 Aug; 2(4):365-9. PubMed ID: 1797192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Extended radical mastectomy using preoperative local injection of activated carbon particle adsorbing aclarubicin (ACR-CH)].
    Asaga T; Kobayashi O; Masuzawa C; Motohashi H; Okamoto T
    Nihon Geka Gakkai Zasshi; 1990 Mar; 91(3):313-9. PubMed ID: 2359386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation.
    Lauria F; Raspadori D; Ventura MA; Rondelli D; Zinzani PL; Gherlinzoni F; Miggiano MC; Fiacchini M; Rosti G; Rizzi S; Tura S
    Bone Marrow Transplant; 1996 Jul; 18(1):79-85. PubMed ID: 8831999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmentation of organ-associated natural killer activity by biological response modifiers. Isolation and characterization of large granular lymphocytes from the liver.
    Wiltrout RH; Mathieson BJ; Talmadge JE; Reynolds CW; Zhang SR; Herberman RB; Ortaldo JR
    J Exp Med; 1984 Nov; 160(5):1431-49. PubMed ID: 6491601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiated immune responses after administration of aclacinomycin.
    Orbach-Arbouys S; Andrade-Mena CE; Berardet M; Mathe G
    Int Arch Allergy Appl Immunol; 1982; 68(2):117-21. PubMed ID: 7042586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of human natural killer cells by lipopolysaccharide and generation of interleukin-1 alpha, beta, tumour necrosis factor and interleukin-6. Effect of IL-1 receptor antagonist.
    Conti P; Dempsey RA; Reale M; Barbacane RC; Panara MR; Bongrazio M; Mier JW
    Immunology; 1991 Aug; 73(4):450-6. PubMed ID: 1833315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expansion of functional NK cells in multiple tissue compartments of mice treated with Flt3-ligand: implications for anti-cancer and anti-viral therapy.
    Shaw SG; Maung AA; Steptoe RJ; Thomson AW; Vujanovic NL
    J Immunol; 1998 Sep; 161(6):2817-24. PubMed ID: 9743341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional character and augmentation of lymphocytes in regional lymph nodes of patients with lung cancer.
    Watanabe Y; Hashizume Y; Shimizu J; Yoshida M; Watanabe S; Iwa T; Sakai S; Migita S; Sato H; Murayama T
    Am Rev Respir Dis; 1990 Oct; 142(4):769-74. PubMed ID: 2221581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Signaling through NK cell-associated CD137 promotes both helper function for CD8+ cytolytic T cells and responsiveness to IL-2 but not cytolytic activity.
    Wilcox RA; Tamada K; Strome SE; Chen L
    J Immunol; 2002 Oct; 169(8):4230-6. PubMed ID: 12370353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel immunomodulator, Linomide, stimulates interleukin-2-induced human natural killer (NK) cell and PHA-stimulated T cell proliferation from normal donors.
    Condiotti R; Slavin S; Barak V; Nagler A
    Leuk Res; 1996 Jan; 20(1):57-63. PubMed ID: 8632678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.